NCT04286958Unknown2 期
A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年4月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
The purpose of this study is to assess efficacy and safety of patients who receive camrelizumab as consolidation therapy after radical concurrent chemoradiotherapy in locally advanced ESCC.
详细描述
In this study, 40 patients with locally advanced ESCC will be enrolled. All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age:18 to 75 years old;
- •Histology confirmed as esophageal squamous cell carcinoma;
- •T1bN+M0, T2-4N0-2M0 local progress period;
- •Have previously received radical concurrent chemoradiotherapy;
- •According to RECIST 1.1, at least one measurable lesion;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- •Expected survival period ≥ 12 weeks;
- •Major organ function has to meet the following certeria:
- •For results of blood routine test HB≥90g/L; ANC≥1.5×109/L; PLT≥80×109/L; 2)For results of blood biochemical test ALB≥30g/L; ALT and AST<2.5×ULN; TBIL≤1.5ULN; Serum creatinine ≤1.5ULN;
- •Left ventricular ejection fraction (LVEF) ≥50%;
- •Women of childbearing age must have contraceptive measures or have test pregnancy (serum or urine) enroll the study before 14 days, and the results must be negative, and take the methods of contraception during the test and the last to have drugs after 8 weeks. Men must be contraception or has sterilization surgery during the test and the last to have drugs after 8 weeks;
- •Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.
排除标准
- •Subjects with immunosuppressive medications within 14 days of first administration of study treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (no more than 10 mg / day of prednisolone or other corticosteroids of equivalent pharmaceutical physiological dose);
- •The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, Hyperthyroidism; patients with vitiligo; Asthma has been completely relieved in childhood, and patients who do not need any intervention after adulthood can be included; asthma patients who require bronchodilators for medical intervention cannot be included);
- •Patients with other malignant tumors within 5 years (except for the treated skin basal cell carcinoma and cervical carcinoma in situ);
- •Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV-DNA ≥1000 IU/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of detection of the analytical method) or co-infection with hepatitis B and C, requiring antiviral treatment during the study ; 5.6 months before study drug administration, the following occurred: myocardial infarction, severe / unstable angina pectoris, grade III-IV cardiac insufficiency according to New York Heart Association(NYHA) criteria, uncontrolled arrhythmias (including QTcF interval male> 450 ms, female> 470 ms ,The QTcF interval is calculated using Fridericia formula), symptomatic congestive heart failure, cerebrovascular accidents (including transient ischemic attack or symptomatic pulmonary embolism);
- •6.Severe infections within 4 weeks before study drug administration (eg. Need intravenous drip antibiotics, antifungals or antivirals) or Unexplained fever>38.5℃ during screening visits or on the first scheduled day of dosing; 7.History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 8.Less than 4 weeks from the last clinical trial; 9.History of psychiatric drugs abuse and can't quit or patients with mental disorders; 10.The researchers think inappropriate.
研究组 & 干预措施
Camrelizumab
Experimental
All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.
干预措施: Camrelizumab (Drug)
结局指标
主要结局
Progression free survival (PFS)
时间窗: evaluated in 24 months since the treatment began
Baseline to measured date of progression or death from any cause
次要结局
- Adverse events(up to 24 months)
- Objective response rate (ORR)(tumor assessment every 6 weeks since the treatment began，up to 24 months)
- Durarion of response (DOR)(tumor assessment every 6 weeks since the treatment began，up to 24 months)
- Overall survival (OS)(the first day of treatment to death or last survival confirm date,up to 24 months)
研究者
Jun wang
Director
Hebei Medical University Fourth Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerGastric CancerNCT04258644Beijing Friendship Hospital30
终止
2 期
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)Recurrent GlioblastomaNCT04952571Beijing Sanbo Brain Hospital3
Unknown
2 期
A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCNon-Small Cell Lung CancerNCT04167774Sun Yat-sen University62
Unknown
不适用
Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell CarcinomaRenal Cell CarcinomaNCT04609293Peking University First Hospital30
尚未招募
2 期
A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck CancerHead and Neck NeoplasmsNCT04405154West China Hospital32